SavedAdd your journal

Journals / The Anatolian Journal of Cardiology / 2018 / Cilt: 19 - Sayı: 2

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients

Zhong-ling ZHUO
Hai-peng XİAN
Yan LONG
Chang LIU
Yuan-yuan SUN
Yin-ting MA
Hua GAO
Jing-zhong ZHAO
Xiao-tao ZHAO
Pages
123–129
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The carriage of ABCB1 mutant allele was not significantly associated with CR risk.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate the association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance (CR) in patients with cardiovasculardisease in Beijing district.Methods: In total, 325 patients were enrolled in the study, including 101 experimental group patients and 224 control group patients.
📊
Key Findings & Data:The experimentalgroup was divided into CR group (n=30) and non-CR group (n=71) according to the adenosine diphosphate (ADP)-induced platelet inhibitionrate in thromboelastography (TEG) (ADP-induced platelet inhibition rate of <30% was defined as CR and rate of 30%–100% was defined asnon-CR).
💡
Conclusion & Impact:The carriage of ABCB1 mutant allele was not significantly associated with CR risk.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: To investigate the association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance (CR) in patients with cardiovasculardisease in Beijing district.Methods: In total, 325 patients were enrolled in the study, including 101 experimental group patients and 224 control group patients. The experimentalgroup was divided into CR group (n=30) and non-CR group (n=71) according to the adenosine diphosphate (ADP)-induced platelet inhibitionrate in thromboelastography (TEG) (ADP-induced platelet inhibition rate of <30% was defined as CR and rate of 30%–100% was defined asnon-CR). Genotypes, including CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*17, and ABCB1, were determined using time-of-flightmass spectrometry (Clin-TOF) and Sanger sequencing in all patients.Results: In the experimental group, carriers of CYP2C19 heterozygous (*1/*2, n=46; *1/*3, n=7), and mutation homozygous (*2/*2, n=7; *2/*3, n=3;*3/*3, n=0) genotypes showed significantly lower ADP-induced platelet inhibition rates than noncarriers (*1/*1, n=38; p=0.035 and 0.001, respectively);the carriage of mutant CYP2C19*2 or *3 allele was significantly associated with an increased risk of CR. In contrast, carriers of ABCB1heterozygous (TC, n=50) showed significantly lower ADP-induced platelet inhibition rates than noncarriers (CC, n=39, p=0.097), and there was nosignificant correlation between ABCB1 genotypes and higher CR risk.Conclusion: The carriage of CYP2C19*2 or *3 mutant allele was significantly associated with attenuated platelet response to clopidogrel andincreased CR risk. The carriage of ABCB1 mutant allele was not significantly associated with CR risk.

🔖

Cite This Article

ZHUO, Z., XİAN, H., LONG, Y., LIU, C., SUN, Y., MA, Y., GAO, H., ZHAO, J., ZHAO, X. (2018). Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients. The Anatolian Journal of Cardiology, Cilt: 19 - Sayı: 2, 123–129. https://ajindex.com/articles/365792

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Ragoussis J, Elvidge GP, Kaur K, Colella S. Matrix-assisted laser desorption/ionisation, time-of-flight mass spectrometry in genomics research. PLoS Genet 2006; 2: e100. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 57: 1920-59. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80: 486-501.
  2. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312-9.
  3. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-57.
  4. Chen BL, Zhang W, Li Q, Li YL, He YJ, Fan L, et al. Inhibition of ADPinduced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms. Clin Exp Pharmacol Physiol 2008; 35: 904-8.
  5. Ghasemi Z, Hashemi M, Ejabati M, Ebrahimi SM, Kheiri Manjili H, Sharafi A, et al. Development of a High-Resolution Melting Analysis Method for CYP2C19*17 Genotyping in Healthy Volunteers. Avicenna J Med Biotechnol 2016; 8: 193-9.
  6. Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998; 8: 129-35.
  7. Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998; 284: 356-61.
  8. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 1996; 6: 521-6.
  9. Chang M, Dahl M